Stockscreener 앱 받기
1.19
11.85%
-0.16
시간 외 거래:
1.16
-0.03
-2.52%
전일 마감가:
$1.35
열려 있는:
$1.4
하루 거래량:
282.40K
Relative Volume:
1.35
시가총액:
$4.45M
수익:
$10.48M
순이익/손실:
$-37.74M
주가수익비율:
-0.0735
EPS:
-16.1846
순현금흐름:
$-29.03M
1주 성능:
+8.18%
1개월 성능:
-33.15%
6개월 성능:
-65.90%
1년 성능:
-95.09%
1일 변동 폭
$1.16
$1.43
1주일 범위
$1.05
$1.50
52주 변동 폭
$1.00
$33.25
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.19 | 5.04M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Central New Jersey News
Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada
Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus
Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com
Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan
Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union
Jaguar Health Inc (JAGX) is looking forward to a strong quarter - setenews.com
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - Sarasota Herald-Tribune
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - The Florida Times-Union
FDA extends conditional approval for Jaguar Health’s canine drug By Investing.com - Investing.com Australia
FDA extends conditional approval for Jaguar Health’s canine drug - Investing.com
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Daytona Beach News-Journal
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Bluffton Today
Jaguar Health announces promising trial results for crofelemer - MSN
Jaguar Health Announces Promising Trial Results for Crofelemer - TipRanks
Jaguar Health (NASDAQ: JAGX) clears all special meeting items, notes MVID trial progress - Stock Titan
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Livingston Daily
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - Daily Commercial
Sakthi Sugars Limited (SAKHTISUG) vs yyyFibonacci Extensions & Free Gain Edge With Data - earlytimes.in
JAGX S-3/A及美國證券交易委員會申報文件 - Yahoo 財經
How dovish Fed policy supports Jaguar Health Inc. (1JA0) stockJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - Newser
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):